相似文献
1
Hypoxia-induced Maspin Expression Affects the Prognosis of Ovarian Clear Cell Carcinoma.
In Vivo. 2022 Jan-Feb;36(1):212-220. doi: 10.21873/invivo.12693.
2
Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma.
J Ovarian Res. 2020 Apr 15;13(1):38. doi: 10.1186/s13048-020-00641-8.
3
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
Gynecol Oncol. 2017 Nov;147(2):243-249. doi: 10.1016/j.ygyno.2017.08.004. Epub 2017 Aug 12.
4
Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes.
EBioMedicine. 2019 Dec;50:203-210. doi: 10.1016/j.ebiom.2019.11.017. Epub 2019 Nov 21.
5
Association of the hypoxia-inducible factor-1α (HIF-1α) gene polymorphisms with prognosis in ovarian clear cell carcinoma.
J Ovarian Res. 2019 Jan 24;12(1):7. doi: 10.1186/s13048-019-0481-9.
6
MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53.
Oncotarget. 2016 Nov 15;7(46):75328-75338. doi: 10.18632/oncotarget.12175.
7
Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.
Gynecol Oncol. 2006 Jun;101(3):390-7. doi: 10.1016/j.ygyno.2006.02.014. Epub 2006 Mar 21.
8
Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma.
J Mol Med (Berl). 2018 Jun;96(6):527-536. doi: 10.1007/s00109-018-1643-8. Epub 2018 May 3.
9
Expression and significance of CD44, CD47 and c-met in ovarian clear cell carcinoma.
Int J Mol Sci. 2015 Feb 4;16(2):3391-404. doi: 10.3390/ijms16023391.
10
Maspin expression is characteristic for cisplatin-sensitive ovarian cancer cells and for ovarian cancer cases of longer survival rates.
Int J Gynecol Pathol. 2006 Apr;25(2):131-9. doi: 10.1097/01.pgp.0000183050.30212.2f.
引用本文的文献
1
The Role of Hypoxia-Inducible Factor-1α (HIF-1α) in the Progression of Ovarian Cancer: Perspectives on Female Infertility.
Cells. 2025 Mar 14;14(6):437. doi: 10.3390/cells14060437.
2
CD8 + T cell infiltration is associated with improved survival and negatively correlates with hypoxia in clear cell ovarian cancer.
Sci Rep. 2023 Apr 21;13(1):6530. doi: 10.1038/s41598-023-30655-3.
3
Computed Tomography Imaging-Based Radiogenomics Analysis Reveals Hypoxia Patterns and Immunological Characteristics in Ovarian Cancer.
Front Immunol. 2022 Mar 28;13:868067. doi: 10.3389/fimmu.2022.868067. eCollection 2022.
本文引用的文献
1
Association between pelvic inflammatory disease and risk of ovarian cancer: An updated meta-analysis.
Gynecol Oncol. 2020 May;157(2):542-548. doi: 10.1016/j.ygyno.2020.02.002. Epub 2020 Feb 7.
2
The prognostic significance of high/positive expression of tissue VEGF in ovarian cancer.
Oncotarget. 2018 Jul 17;9(55):30552-30560. doi: 10.18632/oncotarget.25702.
3
Serum Vascular Endothelial Growth Factor-A as a Prognostic Biomarker for Epithelial Ovarian Cancer.
Int J Gynecol Cancer. 2017 Sep;27(7):1325-1332. doi: 10.1097/IGC.0000000000001027.
4
Clear-cell carcinoma of the ovary.
Ann Oncol. 2016 Apr;27 Suppl 1:i50-i52. doi: 10.1093/annonc/mdw086.
5
Molecular responses to hypoxia-inducible factor 1α and beyond.
Mol Pharmacol. 2014 May;85(5):651-7. doi: 10.1124/mol.113.089623. Epub 2014 Feb 25.
6
Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy.
Endocrinology. 2012 Apr;153(4):1593-602. doi: 10.1210/en.2011-2123. Epub 2012 Mar 13.
7
The microtubule cytoskeleton is required for a G2 cell cycle delay in cancer cells lacking stathmin and p53.
Cytoskeleton (Hoboken). 2012 May;69(5):278-89. doi: 10.1002/cm.21024. Epub 2012 Mar 29.
8
Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis.
Gynecol Oncol. 2011 Sep;122(3):541-7. doi: 10.1016/j.ygyno.2011.05.009. Epub 2011 Jun 2.
9
Immunohistochemical evidence for the over-expression of Glutathione peroxidase 3 in clear cell type ovarian adenocarcinoma.
Med Oncol. 2011 Dec;28 Suppl 1:S522-7. doi: 10.1007/s12032-010-9659-0. Epub 2010 Aug 21.
10
Small interfering RNA-mediated silencing of heat shock protein 27 (HSP27) Increases chemosensitivity to paclitaxel by increasing production of reactive oxygen species in human ovarian cancer cells (HO8910).
J Int Med Res. 2009 Sep-Oct;37(5):1375-88. doi: 10.1177/147323000903700512.
Zotero 插件